Certified by Founder Lodge
Eli Lilly and Company
United States - Indianapolis, Indiana
INVESTOR
1 Disclosed Funding Rounds $97,000,000
164 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs,
| Company | Date | Round | Raised |
|---|---|---|---|
 Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
 Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
 Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
 Amber Bio |
August, 04 ,2023 | Seed | $26,000,000 |
 Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
 Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
 Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
 OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
 Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
 Volastra Therapeutics |
March, 08 ,2023 | Series A | $60,000,000 |
 Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Amber Bio |
August, 04 ,2023 | Seed | $26,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
 DiogenX |
May, 11 ,2023 | Series A | $30,056,125 |
| Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
| Volastra Therapeutics |
March, 08 ,2023 | Series A | $60,000,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
| Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| Volastra Therapeutics |
March, 08 ,2023 | Series A | $60,000,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Amber Bio |
August, 04 ,2023 | Seed | $26,000,000 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
| Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| DiogenX |
May, 11 ,2023 | Series A | $30,056,125 |
| Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| Volastra Therapeutics |
March, 08 ,2023 | Series A | $60,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
| DiogenX |
May, 11 ,2023 | Series A | $30,056,125 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
 Capstan Therapeutics |
March, 21 ,2024 | Series B | $175,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Amber Bio |
August, 04 ,2023 | Seed | $26,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| DiogenX |
May, 11 ,2023 | Series A | $30,056,125 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Volastra Therapeutics |
March, 08 ,2023 | Series A | $60,000,000 |
| Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
| Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
| DiogenX |
May, 11 ,2023 | Series A | $30,056,125 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| Capstan Therapeutics |
March, 21 ,2024 | Series B | $175,000,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
 Mozart Therapeutics, Inc |
June, 08 ,2023 | Series A | $25,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
| Volastra Therapeutics |
March, 08 ,2023 | Series A | $60,000,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| DiogenX |
May, 11 ,2023 | Series A | $30,056,125 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| DiogenX |
May, 11 ,2023 | Series A | $30,056,125 |
| Capstan Therapeutics |
March, 21 ,2024 | Series B | $175,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
| Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Capstan Therapeutics |
March, 21 ,2024 | Series B | $175,000,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Mozart Therapeutics, Inc |
June, 08 ,2023 | Series A | $25,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| DiogenX |
May, 11 ,2023 | Series A | $30,056,125 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| DiogenX |
May, 11 ,2023 | Series A | $30,056,125 |
| Capstan Therapeutics |
March, 21 ,2024 | Series B | $175,000,000 |
| Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Mediar Therapeutics |
March, 15 ,2023 | Unknown | $105,000,000 |
| Capstan Therapeutics |
March, 21 ,2024 | Series B | $175,000,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Mozart Therapeutics, Inc |
June, 08 ,2023 | Series A | $25,000,000 |
| Laverock Therapeutics |
September, 28 ,2023 | Seed | $16,470,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| Vianautis |
November, 14 ,2023 | Series A | $25,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Mozart Therapeutics, Inc |
June, 08 ,2023 | Series A | $25,000,000 |
| Switch Therapeutics |
March, 15 ,2023 | Series A | $52,000,000 |
| Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
 AltPep |
June, 26 ,2023 | Series B | $53,000,000 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
| Mariana Oncology |
September, 08 ,2023 | Series B | $175,000,000 |
| Therini Bio, Inc. |
April, 27 ,2023 | Series A | $36,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| DiogenX |
May, 11 ,2023 | Series A | $30,056,125 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
| OrsoBio |
November, 08 ,2023 | Series A | $60,000,000 |
Truemeds India
Receptor Life Sciences, Inc.
Koneksa
MAYD: MEDS AT YOUR DOORSTEP
Fullife Healthcare Pvt. Ltd.
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
